Table 2.

Summary of Treatment related adverse events.

	First line			Second or later line
	All Grade, n (%)	Grade 3, n (%)	Grade 4, n (%)	All Grade, n (%)	Grade 3, n (%)	Grade 4, n (%)
Any adverse events	6 (100)	5 (83)	2 (33)	22 (100)	14 (64)	10 (45)
Leukopenia	4 (67)	0	1 (17)	20 (91)	3 (14)	3 (14)
Neutropenia	5 (83)	2 (33)	2 (33)	20 (91)	3 (14)	10 (45)
Lymphopenia	2 (33)	0	1 (17)	15 (68)	3 (14)	3 (14)
Anemia	5 (83)	0	0	20 (91)	2 (9)	0
Thrombocytopenia	3 (50)	1 (17)	0	4 (18)	0	0
Mucositis oral	2 (33)	1 (17)	0	4 (18)	0	0
Sore throat	1 (17)	0	0	2 (9)	0	0
Hiccups	1 (17)	0	0	0	0	0
Constipation	1 (17)	0	0	6 (27)	0	0
Diarrhea	1 (17)	0	0	0	0	0
Appetite loss	3 (50)	0	0	10 (45)	0	0
Fatigue	4 (67)	1 (17)	0	10 (45)	0	0
Alopecia	3 (50)	0	0	3 (14)	0	0
Limb edema	1 (17)	0	0	3 (14)	0	0
Arthralgia	2 (33)	0	0	0	0	0
Myalgia	1 (17)	0	0	1 (5)	0	0
Dizziness	1 (17)	0	0	1 (5)	0	0
Peripheral neuropathy	4 (67)	1 (17)	0	7 (32)	0	0
Rash	2 (33)	0	0	3 (14)	0	0
Skin (Folliculitis)	1 (17)	0	0	0	0	0
Infection	3 (50)	1 (17)	0	5 (23)	1 (5)	0
Febrile neutropenia	1 (17)	1 (17)	0	3 (14)	3 (14)	0
AST elevation	4 (67)	0	0	13 (59)	0	0
ALT elevation	2 (33)	0	0	7 (32)	0	0
ALP elevation	3 (50)	0	0	6 (27)	0	0
Hypokalemia	0	0	0	5 (23)	0	0

AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase.